Access

News and Views


Nature Medicine 13, 129 - 131 (2007)
doi:10.1038/nm0207-129

Seeing what Alzheimer saw

Mony J de Leon1, Lisa Mosconi1 & Jean Logan1

  1. M.J. de Leon is at the Center for Brain Health at the New York University School of Medicine, 560 First Avenue, New York, New York 10016, USA, Nathan Kline Institute, Orangeburg, New York 10962, USA. e-mail: mony.deleon@med.nyu.edu
  2. L. Mosconi is at the Center for Brain Health at the New York University School of Medicine, 560 First Avenue, New York, New York 10016, USA.
  3. J. Logan is at the Brookhaven National Lab, Upton, New York 11973 USA.


The ability to visualize brain pathology in living individuals with Alzheimer disease could change how the disease is diagnosed and drugs to treat it tested. A recently developed positron emission tomography tracer helps to image fibrillar amyloid-beta and neurofibrillary tangles and brings us closer to this goal.


Since Alois Alzheimer's seminal report in November of 1906, pathologists have regarded amyloid-beta deposits in senile plaques and neurofibrillary tangles as essential for the diagnosis of Alzheimer disease. In the past 30 years, progress has been made in developing biomarkers to bridge the gap between the 'gold standard' of post-mortem neuropathological confirmation and the clinical diagnosis of Alzheimer disease based on the recognition of cognitive deficits and exclusion of other dementing disorders1.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Seeing what Alzheimer saw

Nature Medicine News and Views (01 Feb 2007)

Pinpointing plaques with PIB

Nature Medicine News and Views (01 Jul 2006)

See all 12 matches for News And Views